XML 32 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Organization of Business and Going Concern (Details Narrative)
9 Months Ended
Mar. 14, 2017
Apr. 30, 2018
USD ($)
Jan. 18, 2017
Reverse stock split ratio 0.001    
Accumulated deficit   $ 424,000,000  
Working capital deficiency   23,000,000  
Non-refundable initial payment   $ 700,000  
License and Research Agreement terms  

In exchange for the License, Shenzhen has agreed, inter alia, to the following financial consideration:

 

  a $700,000 non-refundable initial payment;

 

  milestone payments of $1,000,000 each upon completion of Phase II and Phase III studies;

 

  a milestone payment of $2,000,000 upon regulatory approval of a product covered by the License; and

 

  a 10% royalty on net sales, provided the patents are in force and there are no approved generic equivalents.

 

 
Hema Diagnostic Systems, LLC      
Majority interest     51.00%